We studied the genotoxic and apoptosis-inducing properties of ganciclovir (GCV) and penciclovir (PCV) using Chinese hamster ovary cells stably transfected with the thymidine kinase (tk) gene of herpes simplex virus-1 (HSV-1). Cells expressing HSVtk were 300 and 100 times more sensitive than their isogenic HSVtk Ϫ counterparts to the cytotoxic effects of GCV and PCV, respectively.
S
ince the pioneering work of Moolten, 1 who showed that, by transduction of a herpesvirus-encoded gene, tumor cells can be made specifically susceptible to the toxic action of an antiviral drug and thereby killed, this novel design of gene therapeutic treatment of malignant diseases has gained much interest. The rationale of this approach relies on the fact that herpesviruses encode nucleoside kinases (e.g., the thymidine kinase (TK) of herpes simplex virus (HSV) type 1, which, owing to their less stringent substrate specificity, are able to monophosphorylate nucleoside analogs). This action is in opposition to cellular nucleoside kinases, which are unable to do so or only to a very limited extent. Further metabolization by cellular nucleotide kinases leads to nucleoside analog triphosphates, which compete with deoxyguanosine triphosphate for incorporation into the growing DNA chain and are considered to be the ultimate toxic metabolites acting at DNA polymerases. The proper mechanism of their antiviral activity has not yet been fully elucidated. It appears to differ depending upon the structure and properties of the different nucleoside analogs.
By transducing tumor cells with the tk gene of HSV-1 (HSVtk) and by the systemic administration of the antiviral drug ganciclovir (GCV), it has been shown that the transgene acts as a "suicide gene" that specifically kills those cells that express HSVtk by triggering programmed cell death (apoptosis). [1] [2] [3] Moreover, not only the HSVtk ϩ cells are killed in this way but also nontransduced cells situated nearby (bystander effect), despite the fact that nucleoside phosphates (nucleotides) cannot freely cross cell membranes. It has been shown that gap junctional intercellular communications mediate nucleotide transfer and, thus, bystander killing. 4 -6 A cellmediated immune component appears to contribute to the bystander effect as well. 7, 8 The feasibility and anti-tumor efficacy of the HSVtk gene transfer/GCV treatment schedule has been proven in various experimental in vitro and in vivo systems and, since 1991, several clinical trials are ongoing for the gene therapy of brain tumors, ovarian carcinomas, head and neck tumors, and other kinds of tumors. 9 -11 The initial results from these trials have been published recently. 12, 13 It appears that the main problems still limiting the therapeutic utility are the insufficient transducing capacity of the retroviral vector-producing cell lines that carry the therapeutic gene, its limited distribution within the tumor tissue, and, last but not least, the tumor-specific capacity of gap junction formation that determines the bystander effect.
Probably most promising will be the use of the suicide gene/GCV design in allogeneic bone marrow transplantation for the treatment of hematopoietic malignancies. Highly sophisticated methods of lymphocyte culture and immunomagnetic cell sorting permit selection of a nearly 100% pure population of HSVtk-transduced donor lymphocytes ready for transplantation into tumor patients, thus achieving the graft-versus-tumor effect. As the infused lymphocytes expressed the HSVtk gene for long periods of time, it was possible, by GCV administration, to control the graft-versus-host disease, which represents a frequent and potentially lethal complication in allogeneic bone marrow transplantation for which so far no specific therapy has been available. Initial experiences with this method were very encouraging and promise long-term curative responses. 14, 15 Although in most cases during cancer chemotherapy the use of genotoxic drugs appears acceptable as long as no safer alternative exists, potentially genotoxic drugs should be avoided for the treatment of curable diseases because they might induce secondary neoplasias. Agents such as GCV, which, by their structure and mode of action, interfere with nucleic acid metabolism, are clearly suspected of exerting genotoxic damage. Although frequently used at present, hardly any detailed investigations addressing this issue for GCV and other antiviral nucleoside analogs have been published so far. GCV is mainly used in the therapy of cytomegalovirus (CMV) diseases in immunocompromised patients, particularly in transplant recipients and in AIDS cases in which CMV reactivations may pose a life-threatening condition causing interstitial pneumonia. This may lead to transplant rejection or retinitis, which is one of the most severe complications in AIDS patients. 16 However, GCV is known for its adverse effects, particularly for bone marrow toxicity. Also, according to the manufacturer, the drug may cause hereditary damage and should be considered as a potential carcinogen. 17 In a previous study, we checked the genotoxicity of a series of antiherpes purine nucleosides in genetically unmodified Chinese hamster V79-E cells and observed a considerable activity of GCV even in the range of the 50% inhibitory concentration of the CMV (Ͻ10 M) (i.e., below therapeutic concentrations achieved in the clinical setting). 18 It became obvious in this study, however, that a relevant assessment of the genetic risk of GCV can only be made using metabolically competent indicator cells (i.e., cells expressing herpesvirus-encoded nucleoside kinases that are responsible for the therapeutic activity of the drug). To our best knowledge, such investigations have not been conducted thus far.
Here we report on the genotoxicity of GCV and penciclovir (PCV), a congener of GCV that is used for the therapy of herpes zoster, in Chinese hamster ovary (CHO) cells stably transfected with the tk gene of HSV-1. The cell lines we generated are highly sensitive to the induction of genetic damage by GCV compared with their isogenic HSVtk Ϫ counterparts. With respect to the induction of recombinations (as measured by sister chromatid exchanges (SCEs)) and chromosomal aberrations, GCV appears to be a very active agent that is comparable with strong alkylating DNA-damaging clastogens. Moreover, we observed that GCV is highly cytotoxic by triggering the apoptotic pathway. Comparing the genotoxicity of GCV with that of PCV, we became aware that the latter drug very effectively induced apoptosis in HSVtk-transfected CHO cells. Interestingly, despite this, PCV was largely devoid of strong genotoxic activity. Thus it appears that PCV, which has so far not been studied as to its suitability for apoptosis induction, might be a safer alternative than GCV for the suicide gene therapy concept of malignant diseases.
In addition, to compare the genotoxic and apoptotic activity of GCV and PCV, we were interested in elucidating the mechanisms of induction of SCEs and chromosomal changes by these compounds. We report that GCV and, to a much lesser extent, PCV are incorporated into the genomic DNA of HSVtk-transfected cells, and that the decisive genotoxic events are triggered in the postexposure DNA replication cycle.
MATERIALS AND METHODS

Chemicals
GCV (9-[1,3-dihydroxy-2-propoxymethyl]-guanine/GCV, Cymevene) was purchased from Syntex Arzneimittel (Aachen, Germany) and dissolved in complete culture fluid. PCV (9-[4-hydroxy-3-hydroxybut-1-yl]-guanine/PCV) was a gift from SmithKline Beecham (Hamburg, Germany). It was dissolved in a small volume of 0.3 N NaOH and subsequently diluted in complete culture fluid. If necessary, the medium was neutralized with 0.2 N HCl.
Radiolabeled GCV and PCV, each labeled with tritium at the 8-H position of guanine, were purchased from Moravek Biochemicals (Brea, Calif).
Cells
Cells were grown in Ham's F12/Dulbecco's minimal essential medium (1:1) containing 5% fetal bovine sera or, alternatively, 10% inactivated neonatal bovine sera. To generate HSVtkexpressing cells, CHO-9 cells were cotransfected with the plasmid pMCI-tk (kindly provided by Dr. M. Blessing, University of Mainz, Mainz, Germany) harboring the tk gene of HSV-1 under the control of the tk promoter (10 g per plate) and pSV2neo (2 g per plate) using the calcium phosphate coprecipitation method as described previously. 19 As a control, pSV2neo was cotransfected with salmon sperm DNA. Transfectants were selected with G418 (1.5 mg/mL), and the expres-sion of the HSVtk gene was checked in individual clones by Northern and Western blot analysis. Cells were routinely cultured in medium containing G418, which was omitted during the experiments.
Northern and Western blot analysis mRNA from exponentially growing cells was extracted as described previously. 20 Next, RNA was run on a 1% formaldehyde-4-morpholinepropanesulfonic acid agarose gel, blotted onto a Hybond N ϩ membrane, and hybridized with the radioactively labeled HSVtk gene (specific activity of ϳ5 ϫ 10 8 cpm/g DNA). 20 Hybridization was performed in 7% sodium dodecyl sulfate (SDS), 0.5 M Na 2 HPO 4 (pH 7.2), and 1 mM ethylenediaminetetraacetic acid overnight. For washing, decreased concentrations of standard saline citrate (2ϫ, 1ϫ) and 0.5% SDS were used at 60°C. Filters were stripped by incubating in 1% SDS at 80°C for 30 minutes and were rehybridized with glyceraldehyde-3-phosphate dehydrogenase as a loading control. For immunohistochemical analysis, cell extracts obtained by sonification of cells in 20 mM tris(hydroxymethyl) aminomethane-HCl (Tris-HCl) (pH 8.5), 1 mM ethylenediaminetetraacetic acid (EDTA), 2 mM dithiothreitol, 0.5 mM phenylmethylsulfonyl fluoride, and 5% glycerol were loaded onto a 7.5% polyacrylamide gel and run for 2 hours at 35 mA. The separated proteins were transferred to a 0.2-m cellulose nitrate membrane using a buffer consisting of 25 mM Tris-HCl 86 mM glycine, and 20% methanol. To avoid unspecific binding, filters were incubated in 5% nonfat dry milk and 0.1% Tween 20 in phosphate-buffered saline (PBS) for 3 hours. Thereafter, filters were incubated with a polyclonal antibody (Ab) directed against the TK of HSV-1 (1:10,000) (kindly provided by Dr. M. Black, Darwin Molecular Corporation, Bothell, Wash). As a secondary Ab, horseradish peroxidaseconjugated anti-rabbit immunoglobulin G was used (Amersham, Arlington Heights, Ill) (1:5000). For loading control, filters were incubated with polyclonal rabbit extracellular regulated kinase-2 (ERK2) Ab (Santa Cruz Biotechnology, Santa Cruz, Calif). The protein Ab complexes were visualized by enhanced chemiluminescence (Amersham) according to the manufacturer's protocol.
Incorporation of GCV and PCV into genomic DNA
A total of 2 ϫ 10 5 CHO-HSVtk ϩ cells were seeded on 10-cm dishes, grown for 3 days, and subsequently treated for 14 hours with [ 3 H]-GCV (specific activity of 13.1 Ci/mmol) or [ 3 H]-PCV (specific activity of 17.6 Ci/mmol), respectively. The cells were harvested by trypsinization immediately after treatment, and DNA was isolated using the QIAamp Blood Kit 50 from Qiagen (Hilden, Germany) according to the manufacturer's protocol. The DNA pellet was dissolved in 400 L of TE buffer (10 mM Tris-HCL, 1 mM EDTA) (pH 8.0), and the amount of the isolated DNA was measured by ultraviolet spectrophotometry. The amounts of GCV and PCV incorporated into DNA were calculated from the specific radioactivity of the isolated DNA and the specific activity of the drugs. In parallel control experiments with nontransfected CHO cells, significant drug incorporation was not observed.
Survival assay
Two different conditions were used to measure cytotoxicity after drug treatment: (a) mass cultures of exponentially growing cells were treated with GCV or PCV for 14 hours and cells were subsequently trypsinized and plated for the determination of colony-forming ability in the usual manner; alternatively, (b) exponentially growing cells were seeded at a density of 150 cells per 3.5-cm well of Costar clusters and treated 6 hours later with various concentrations of the nucleoside analogs by adding 10-fold stock solutions directly to the medium. In this case, the drugs were left in the cultures for 7 days. This latter experimental design was chosen because it closely resembles the clinical situation in which GCV or PCV must be continuously present for efficient antiviral or suicide gene therapy. In both cases, the colonies were rinsed with PBS after 7 days, fixed in methanol, and stained with crystal violet. Relative cell survival was calculated from the number of colonies per well (at least three wells per condition) in relation to the untreated controls.
SCE and clastogenicity assays
Asynchronously growing cells were seeded at a density of 3 ϫ 10 5 cells per 25-cm 2 flask. Experiments were started 1 day later. In general, drug exposure lasted for 14 hours, followed by careful rinsing and cultivation for recovery periods of different lengths in agent-free medium. Cultures provided for SCE detection received 5-bromodeoxyuridine (BrdU) (10 g/mL), whose presence is necessary for two cell cycles to produce sister chromatid differentiation. Cells were harvested and fixed at different times after BrdU labeling and drug exposure. The following treatment schedules were applied: 0 hours of recovery (14 hours of prelabeling with BrdU plus 14 hours of drug exposure in the presence of BrdU), 14 hours of recovery (14 hours of drug plus BrdU exposure followed by 14 hours of drug-free BrdU postlabeling), 28 hours of recovery (14 hours of drug exposure plus 28 hours of culture in BrdU-containing drug-free medium), and 42 hours of recovery (14 hours of drug exposure plus 14 hours of culture in normal medium plus 28 hours of BrdU postlabeling). Chromosome preparations were made in the usual manner after trypsinization of the cultures. For metaphase arrest, colcemid (0.05 g/mL) was added during the last 3 hours prior to preparation. SCEs were visualized using a modified fluorescence plus Giemsa technique. 21 A total of 30 stemline metaphases per sample were enumerated for SCE induction. Clastogenicity was evaluated in 200 metaphases per sample of preparations stained by conventional Giemsa stain. The aberration types scored were: chromatid and isochromatid gaps, chromatid and isochromatid breaks, translocations, dicentric and ring chromosomes, and premature chromosome condensations. All exposure conditions were checked at least twice in independent experimental series and gave highly consistent data.
Apoptosis and necrosis: Annexin V assay
To monitor drug-induced apoptosis and necrosis within the same cell population, annexin V/propidium iodide double staining combined with flow cytometry was used. 22 This assay allows the quantitation of different cell populations: living cells that were not labeled by either annexin V or propidium iodide, necrotic cells that were stained by both agents, and apoptotic cells that were labeled only by annexin V. Exponentially growing CHO-HSVtk ϩ cells were treated with increasing concentrations of GCV or PCV for 14 hours. The cells were trypsinized after different postexposure periods, washed with cold PBS, and subjected to the assay according to the manufacturer's protocol (ApoScreen annexin V apoptosis kit, Dianova, Hamburg, Germany). For time course experiments, exponentially growing cells were treated for 14 hours with 1 M of GCV or 5 M of PCV, respectively. Next, cells were rinsed with PBS and grown in fresh medium until harvest at the timepoints indicated. Measurements were performed using a flow cytometer from Becton Dickinson (CellQuest program) (Mountain View, Calif).
RESULTS
Generation of HSVtk-transfected cells
Various independently derived stable HSVtk transfectants were established expressing HSVtk mRNA ( Fig  1A) and protein (Fig 1B) . For further studies, the clones TM8 CHO-neo1-C2 (control cells transfected with the neo gene only) and TM8 CHO-3-C2 (transfected with neo plus HSVtk gene) were chosen (designated below as CHO-neo and CHO-HSVtk ϩ cells, respectively). As shown in Figure 2 , CHO-HSVtk ϩ cells are clearly more sensitive than the corresponding CHO-neo control to the cytotoxic effects of GCV and PCV as measured by colony formation. This difference in sensitivity was most distinct upon continuous drug exposure (Fig 2C) , but pulse treatment for 14 hours (Fig 2, A and B) showed, in principle, similar differences between HSVtk ϩ and HSVtk Ϫ CHO cells. The survival rate was reduced to Ͻ10 Ϫ4 with a concentration of 1-3 M of the drugs (chronic exposure). Similar killing effects were observed in neo cells with 300-fold higher doses of the drugs. It should be noted that, on molar basis, GCV was slightly Western blot analysis. A total of 50 g of total cell extract protein was separated per slot. The filter was reincubated with ERK2 Ab to demonstrate equal loading. Double bands in the case of TM8 CHO-3-C2 and TM8 CHO-3-C5 represent the unstripped TK protein (upper band) and the ERK2 protein (lower band). TM8 CHOneo1-C2 is the neo-transfected control clone, whereas the other clones were generated from cotransfection with the HSVtk gene. Of these, only TM8 CHO-3-C2 and TM8 CHO-3-C5 expressed HSVtk. Clone TM8 CHO-3-C2 has been used in the other studies. more effective (ϳ3-fold) than PCV in inducing cell killing both in CHO-HSVtk ϩ and in CHO-neo cells.
Incorporation of GCV and PCV into genomic DNA of CHO-HSVtk ϩ cells
Exponentially growing cells were exposed to tritiumlabeled GCV and PCV for a period of 14 hours, which represents the average generation time of the cell line. As shown in Figure 3A, Cell cycle dependence of SCE and aberration production In initial clastogenicity experiments using different exposure periods with various agent-free culture periods thereafter, we found that genotoxicity was essentially dependent upon the duration of drug exposure and the time of chromosome preparation after treatment. This indicated a cell cycle dependence in the generation of the genotoxic effects of GCV and PCV (data not shown). To gain further insight into the mode of genotoxic action of the drugs, experiments were conducted by exposing cells to the drugs for the period of one cell cycle and measuring genotoxic effects as a function of time thereafter. Using this approach, we aimed to see whether the treatment itself or postexposure events are responsible for inducing genotoxicity.
SCEs are highly sensitive indicators of DNA damage. As shown in Figures 4 and 5 , both GCV and PCV are effective in inducing SCEs, but GCV was much more potent than PCV. Interestingly, for both agents the SCE frequency did not exceed background levels if the cells were evaluated immediately after drug exposure (postexposure time 0). SCE frequency rose, however, after an additional 14 hours of postexposure and increased with longer postexposure periods. Thus, the data clearly indicate that the SCEs induced by GCV and PCV were not formed during the drug exposure cycle. They obviously arose from lesions generated in the DNA during consecutive cell cycle(s).
Basically similar findings were obtained for the end point chromosomal aberrations. Both GCV and PCV did not induce aberrations immediately after 14 hours of drug exposure. However, aberration frequency increased significantly with increasing postexposure time (Fig 6) . This again indicates that chromosomal aberrations were not formed during the exposure cycle of GCV or PCV, and that later events are decisive in causing clastogenic effects. GCV induced mainly chromatid breaks and chromatid translocations. It is remarkable that PCV was quite inefficient in this respect, but predominantly induced chromosome condensation defects (partial and total premature chromosome condensations). It seems that these effects of PCV are mainly caused by an uncoupling of DNA replication and mitosis and an inhibition of cytokinesis. This will be addressed separately (our manuscript in preparation).
Necrosis and apoptosis induced by GCV and PCV
For these studies, the same experimental conditions were chosen that were applied for the cytogenetic assays (i.e., 14 hours of drug exposure of exponentially growing cells). As shown in Figure 7 , both GCV and PCV were able to induce apoptosis in CHO-HSVtk ϩ cells. The frequency of the induction of apoptosis was clearly dependent upon postincubation time (Fig 8) . It increased dramatically at late timepoints after drug exposure (48 and 72 hours). Thus, it appears that cell killing 
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due to apoptosis induced by GCV and PCV is a lateevent. For both agents, the frequency of induced apo-ptosis was remarkably high (Յ70% at 72 hours postincubation), whereas the yield of necrotic cells was not significantly enhanced. Thus, the majority of cell killing effects observed for GCV and PCV appears to be due to apoptosis. Basically similar findings were obtained with the terminal deoxynucleotidyltransferasemediated deoxyuridine triphosphate nick-end labeling assay and the cell death detection ELISA (data not shown), which detect DNA strand breaks or nucleosomal fragmentation, respectively, and are indicators of ongoing apoptosis.
Comparison of GCV and PCV as to genotoxic potency
As shown above, GCV is an extraordinary effective genotoxic agent in CHO cells expressing the HSVtk gene. With 0.11 M of GCV, a dose that does not affect cell survival, and 28 or 42 hours of recovery, the SCE rates reached the limit of countability. Higher GCV concentrations caused increasing cell cycle delay that prevented sister chromatid contrast. SCE induction by GCV was a long-lasting phenomenon: statistically significant SCE increases were observed with 0.11 M even at 120 hours postexposure (data not shown). A distinct no-effect threshold of SCE induction by GCV was not found. A concentration as low as 1 nM still induced a statistically significant increase of SCEs. In contrast to GCV, PCV induced SCEs at concentrations that were clearly cytotoxic, and the maximum SCE rates obtained were only about four times the background rate (Fig 5) .
A concentration and recovery time dependence of the genotoxic activity of GCV was also observed in the less sensitive clastogenicity assay (Fig 6) . With a concentration of 0.4 M, which is subtoxic in the colony-forming assay, this drug induced ϳ75% aberrant cells at late recovery times. PCV induced a maximum of ϳ35% aberrant cells in the range of toxic concentrations and at late postexposure times (Fig 6) . Furthermore, the ratio of polyploid metaphases increased by Յ8% after exposure to 4 M of PCV and 42 hours of recovery, whereas the rate of polyploid metaphases in untreated and GCV-treated CHO-HSVtk ϩ cells was Ͻ2% (data not shown). PCV (B) . CHO-HSVtk ϩ cells were treated with drugs for 14 hours and analyzed by flow cytometry 72 hours thereafter using the annexin V assay.
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A quantitative comparison of the genotoxic potential of both drugs is shown in Figure 9 , in which the frequencies of SCEs and chromosomal aberrations per given dose level were related to the reproductive cell death induced by the agents (data from Fig 2C; continuous exposure). Basically the same results were obtained when SCE and aberration rates were compared with survival after pulse treatment with the drugs for 14 hours (data not shown). The data clearly reveal that, at equitoxic doses, GCV is much more effective in inducing SCEs and aberrations than PCV.
DISCUSSION
GCV is widely used both as an antiviral drug as well as in suicide gene-mediated tumor therapy. Upon uptake by metabolically competent cells, both GCV and PCV are rapidly monophosphorylated and converted to the respective triphosphates, which have a rather long intracellular half-life. [23] [24] [25] [26] Therefore, a high number of cells may get in contact with the phosphorylated form of the prodrug either due to cellular expression of the HSVtk gene itself or due to intercellular transport of the phosphorylated nucleoside via gap junctions. In both cases, drug treatment may cause a potential hazard for cells that survived the treatment at the expense of genetic damage. Therefore, it is of importance to elucidate the genotoxic potential of the agents in relation to their cytotoxic activity. Here we have shown that GCV is a highly potent genotoxic agent that is able to induce genetic damage even with subtoxic concentrations. This finding is in opposition to PCV, which is, at equitoxic doses, significantly less genotoxic.
The antiviral selectivity of the drugs is currently understood to rely on their preferred monophosphorylation by herpesvirus-encoded nucleoside kinases (thymidine kinases of HSV-1, HSV-2, and varicella-zoster virus) or a protein kinase encoded by the UL97 gene of CMV. 27 The much lower K i values of herpesvirus DNA polymerases, compared with their cellular counterparts, are another factor causing antiviral selectivity of purine nucleoside analogs. The cytotoxic and genotoxic mechanisms of GCV and other antiviral drugs onto the cell itself are still poorly understood. In previously published studies on suicide gene therapy, the mode of action of GCV at the molecular level was assumed to rely on DNA chain termination causing apoptosis. This possibility is unproven, however, and was unwarrantedly concluded from the properties of its congener acyclovir (ACV), which is indeed an absolute chain terminator. Unlike ACV, both GCV and PCV have two hydroxyl groups in their acyclic "sugar" moiety that can form phosphodiester linkages in the DNA backbone. Thus, they can be internally incorporated into the growing DNA chain. The extent to which this happens is still a matter of debate. Experiments with purified DNA polymerases from herpesviruses and mammalian cells and with synthetic primer templates have shown that GCVtriphosphate is terminally incorporated and that the DNA chain is elongated at least one further nucleotide behind GCV-monophosphate followed by chain termination. 28 -30 This finding led to the consideration of GCV as a nonobligate chain terminator. It has been questioned, however, whether these in vitro studies are relevant for the cellular situation considering the complexity of the replication machinery. 28, 31 Moreover, it has been shown that the drug does not interrupt the replication of CMV DNA, but short subgenomic DNA fragments continue to be synthesized leading to an intracellular accumulation of incomplete noninfectious viral DNA fragments. 32 Given these facts, the antiviral and possibly also cytotoxic activity of GCV cannot simply be the result of an inhibition of DNA replication due to chain termination. Our present investigation demonstrates a considerable incorporation of GCV into the genomic DNA of metabolically competent CHO cells. This finding confirms the earlier studies of St. Clair et al, who obtained similar results in HSVtk-expressing mouse fibroblasts. 33 GCV was highly powerful in inducing SCEs and aberrations in the second posttreatment DNA replication cycle. Thus, it appears that replication of a template containing GCV is hampered possibly due to sterical hindrances of DNA polymerase action provided by the incorporated guanine analog. GCV contains an unchanged guanine base and, consequently, is able to form regular Watson-Crick base pairs with deoxycytosine. Physicochemical studies in GCV-containing synthetic oligodeoxynucleotides have recently shown that internal GCV maintains the B conformation of the DNA double helix but reduces its thermal stability. 34 Interestingly, significant distortions in the sugar-phosphate backbone were observed that were localized at or near the site of GCV incorporation, leading to kinks in the helix. 35 An interesting observation gained from our cytogenetic studies is that both GCV and PCV are nonactive in inducing SCEs and aberrations within the cell cycle of treatment. An additional replication cycle was required to induce genotoxic effects. From this we conclude that, at least in the case of GCV, the DNA incorporation step does not give rise to SCEs and aberrations, whereas the postexposure replication cycle is primarily involved. We assume that incorporated GCV may cause DNA helix perturbations that block replication in the consecutive replication cycle. Potentially, replication blocks are considered to be a main source of SCEs and aberrations, whereby SCEs are thought to be the result of recombinational processes that serve to circumvent blocks to replication. 36 One may also speculate that incorporated GCV is subject to repair processes that generate secondary lesions triggering recombination in the consecutive cell cycle.
Structurally, PCV is very similar to GCV, with the exception that the ether oxygen in the aliphatic side chain of the "sugar" in GCV is replaced by a methylene group. Although in vitro studies with DNA polymerase ␣ and HSV-2 DNA polymerase, synthetic primers, and PCV-triphosphate gave results that were similar to those obtained with GCV-triphosphate, data have not been provided thus far that indicate that PCV can be incorporated into genomic DNA during replication. 37, 38 For PCV, much less incorporation into the genomic DNA of CHO-HSVtk ϩ cells was found. PCV was at the same time much less effective than GCV in inducing SCEs and chromosomal aberrations, presumably due to its low ability to become stably incorporated into DNA. The high cell killing potency of PCV in metabolically com-petent cells was unexpected and is remarkable. PCV is in clinical use for the therapy of herpes zoster in the form of its orally administered prodrug famciclovir (9-[4-acetoxy-3-acetoxymethylbut-1-yl]guanine). Upon oral administration, famciclovir becomes almost completely metabolized to PCV by aldehyde oxidase and esterases in the intestinal epithelium and liver, yielding maximum blood plasma concentrations of ϳ13 M.
17,25 This is well above the concentration that induces cell death in tk-transfected cells, as shown here.
Our studies revealed that in the case of both GCV and PCV, a major route of cell killing is apoptosis. The yield of necrotic cells was only marginally enhanced, whereas peak levels of ϳ70% of apoptotic cells were found. Cytotoxicity due to nucleoside analog-induced apoptosis appears to be a late event that becomes manifest two and more cell cycles after exposure to the drugs. Previously it was hypothesized that chromosomal damage may be causally involved in apoptosis. 36 Because PCV is obviously highly potent in inducing apoptosis despite its low clastogenic potential, it cannot be excluded that this drug triggers the apoptotic pathway by a still unknown mechanism that is crucially different from that of GCV. A detailed investigation of this topic is required in our laboratory. In the field of antiviral research, it is a well-known fact that subtle molecular modifications in nucleoside analogs may cause profound changes of biological activity, and that there is no such thing as a "close congener." 39 The effects of PCV observed in cells transfected with the HSVtk gene, compared with those induced by GCV, yield a further example.
The high capacity of PCV to induce apoptosis and ultimately reproductive cell death without eliciting many genotoxic effects is of particular interest in view of the use of the drug in suicide gene cancer therapy. Our results indicate that PCV is probably the drug of choice to be used in clinical settings, rather than GCV, because of the possibility of minimizing long-term genotoxic effects in the treated population.
Finally, we should note that we conducted similar experiments with ACV using HSVtk-transfected CHO cells. ACV induced chromosomal damage and cytotoxic effects similar to those observed with GCV but at concentrations (Ն0.1 mM) that are not achievable in the clinical setting. Presumably, this is caused by the very low intracellular half-life of ACV-triphosphate (0.6 hours), which is much shorter than that of the triphosphates of GCV or PCV. 40 CHO-HSVtk ϩ cells were ϳ10 times more sensitive than CHO-neo cells for cell killing after treatment with ACV (data not shown). The low discrimination between HSVtk ϩ and HSVtk Ϫ cells as to ACVinduced cell killing makes this drug unsuitable for gene therapeutic trials.
Recently, data on the mechanism of GCV-induced cytotoxicity in human glioblastoma cells stably transfected with HSVtk gene have been reported showing that GCV incorporation into the DNA is essential for inducing cytotoxicity. Moreover, it has been shown that this incorporation does not lead to an immediate cessation of DNA replication and to an induction of apoptosis. 41 This observation supports our findings that GCV does not induce SCEs and aberrations as well as apoptosis in the drug incorporation cycle, whereas postincorporation replication is most important for eliciting genotoxic and killing effects.
